← Eichor
Study identifier: NCT06329999 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Condition: Recurrent Adult Acute Myeloid Leukemia · Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia  ·  Sponsor: Ruijin Hospital

PhaseNA
Planned participants78
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The goal of this clinical trial\] is to evaluate mitoxantrone hydrochloride liposomes, subcutaneous injection of cytarabine and G-CSF combined with Venetoclax (CMG+Ven) in adult secondary acute myeloid leukemia and myelodysplastic syndrome with increased primordial cells type 2(MDS-IB2) or elderly acute myeloid leukemia\]. The main questions it aims to answer are: * Evaluation of the efficacy * Evaluation of the safety

This description comes directly from the study's public registry record.

Talk to the study team

Xiaoqian Xu, Doctor  ·  13816205940  ·  Ellenxxq@qq.com

sujiang Zhang, Doctor  ·  Zbruce.zhang@hotmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06329999